SCL Science Inc. (KOSDAQ:246960)

Market Cap	94.61B
Revenue (ttm)	9.36B
Net Income (ttm)	-3.54B
Shares Out	33.97M
EPS (ttm)	-116.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,231
Average Volume	95,348
Open	2,775.00
Previous Close	2,730.00
Day's Range	2,650.00 - 2,775.00
52-Week Range	1,882.50 - 5,110.00
Beta	1.01
RSI	58.50
Earnings Date	Nov 14, 2025

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and I...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.